Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Biology

Epidemiology

Medicine

Microbiology

Internal Medicine

Show all topics

DOI

10.1016/s0140-6736(21)00461-x

License

CC-BY

Other Formats

PDF